S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
NASDAQ:TNXP

Tonix Pharmaceuticals Stock Forecast, Price & News

$0.28
-0.01 (-3.47%)
(As of 01/18/2022 04:00 PM ET)
Add
Compare
Today's Range
$0.27
$0.29
50-Day Range
$0.28
$0.58
52-Week Range
$0.27
$2.12
Volume
10.97 million shs
Average Volume
12.07 million shs
Market Capitalization
$137.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.1
30 days | 90 days | 365 days | Advanced Chart
Receive TNXP News and Ratings via Email

Sign-up to receive the latest news and ratings for Tonix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Tonix Pharmaceuticals logo

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.

Headlines

Fed doubles rate of tapering, eyes 3 rate hikes next year
December 16, 2021 |  finance.yahoo.com
TNXP: Infectious Disease Investments Likely to Pay Off…
December 13, 2021 |  finance.yahoo.com
Why Tonix Pharmaceuticals Is Up by 6% Today
November 23, 2021 |  fool.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TNXP
Employees
26
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.33 per share

Profitability

Net Income
$-50.46 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
491,383,000
Market Cap
$137.96 million
Optionable
Optionable

Company Calendar

Last Earnings
11/07/2021
Today
1/19/2022
Next Earnings (Estimated)
3/21/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.91 out of 5 stars

Medical Sector

710th out of 1,414 stocks

Pharmaceutical Preparations Industry

349th out of 682 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -












Tonix Pharmaceuticals (NASDAQ:TNXP) Frequently Asked Questions

Is Tonix Pharmaceuticals a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tonix Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Tonix Pharmaceuticals stock.
View analyst ratings for Tonix Pharmaceuticals
or view top-rated stocks.

How has Tonix Pharmaceuticals' stock been impacted by Coronavirus?

Tonix Pharmaceuticals' stock was trading at $0.8311 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TNXP stock has decreased by 66.6% and is now trading at $0.2780.
View which stocks have been most impacted by COVID-19
.

When is Tonix Pharmaceuticals' next earnings date?

Tonix Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 21st 2022.
View our earnings forecast for Tonix Pharmaceuticals
.

How were Tonix Pharmaceuticals' earnings last quarter?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) posted its quarterly earnings data on Sunday, November, 7th. The company reported ($0.05) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.02.
View Tonix Pharmaceuticals' earnings history
.

When did Tonix Pharmaceuticals' stock split? How did Tonix Pharmaceuticals' stock split work?

Shares of Tonix Pharmaceuticals reverse split on Wednesday, November 28th 2018. The 1-10 reverse split was announced on Tuesday, November 27th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 27th 2018. An investor that had 100 shares of Tonix Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for TNXP?

1 brokers have issued 12 month target prices for Tonix Pharmaceuticals' stock. Their forecasts range from $2.00 to $2.00. On average, they expect Tonix Pharmaceuticals' share price to reach $2.00 in the next year. This suggests a possible upside of 619.4% from the stock's current price.
View analysts' price targets for Tonix Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Tonix Pharmaceuticals' key executives?

Tonix Pharmaceuticals' management team includes the following people:
  • Seth Lederman, Chairman, President & Chief Executive Officer (LinkedIn Profile)
  • Jessica Edgar Morris, Chief Operating Officer
  • Bradley Saenger, Treasurer & Chief Financial Officer
  • Gregory M. Sullivan, Secretary & Chief Medical Officer

What other stocks do shareholders of Tonix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tonix Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Rite Aid (RAD), Heat Biologics (HTBX), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), VBI Vaccines (VBIV) and ADMA Biologics (ADMA).

What is Tonix Pharmaceuticals' stock symbol?

Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."

How do I buy shares of Tonix Pharmaceuticals?

Shares of TNXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tonix Pharmaceuticals' stock price today?

One share of TNXP stock can currently be purchased for approximately $0.28.

How much money does Tonix Pharmaceuticals make?

Tonix Pharmaceuticals has a market capitalization of $137.96 million. The company earns $-50.46 million in net income (profit) each year or ($0.29) on an earnings per share basis.

How many employees does Tonix Pharmaceuticals have?

Tonix Pharmaceuticals employs 26 workers across the globe.

What is Tonix Pharmaceuticals' official website?

The official website for Tonix Pharmaceuticals is www.tonixpharma.com.

Where are Tonix Pharmaceuticals' headquarters?

Tonix Pharmaceuticals is headquartered at 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022.

How can I contact Tonix Pharmaceuticals?

Tonix Pharmaceuticals' mailing address is 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022. The company can be reached via phone at (212) 980-9155, via email at [email protected], or via fax at 212-923-5700.


This page was last updated on 1/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.